STUDY PROTOCOL

Creation of a rectal cancer registry in Italy by the Advanced International Mini-Invasive Surgery (AIMS) academy clinical research network [version 1; peer review: 3 approved]

Giulio M. Mari ¹, Pietro Achilli ², Dario Maggioni¹, Jacopo Crippa², Andrea T.M. Costanzi¹, Mauro A. Scotti³, Vittorio Giardini³, Mattia Garancini³, Eugenio Cocozza⁴, Giacomo Borroni⁴, Iaria Benzoni⁵, Mario Martinotti⁵, Luigi Totaro⁵, Matteo Origi⁶, Michele Mazzola⁶, Giovanni Ferrari⁶, Antonio Zicarelli⁷, Roberto Petri⁷, Vincenzo Bagnardi⁸, Giacomo Pugliese⁹, Antonello Forgione⁶, Raffaele Pugliese⁹,
AIMS Academy Clinical Research Network

¹General Surgery Department, Desio Hospital, Desio, Italy

²General Surgery Residency Program, University of Milan, Milan, Italy

³General Surgery Department, San Gerardo Hospital, Monza, Italy

⁴General Surgery Department, Varese Hospital, Varese, Italy

⁵Department of Surgery, Cremona Hospital, Cremona, Italy

⁶General Surgery Department, Niguarda Hospital, Milan, Italy

⁷General Surgery Department, AOU "SSMM della Misericordia", Udine, Italy

⁸Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy

⁹AIMS Academy Clinical Research Network, Advanced International Mini-Invasive Surgery (AIMS) Academy, Milan, Italy

V1 First published: 10 Oct 2019, 8:1736
<https://doi.org/10.12688/f1000research.20702.1>

Latest published: 10 Oct 2019, 8:1736
<https://doi.org/10.12688/f1000research.20702.1>

Abstract

Background: The management of rectal cancer is multimodal and involves a multidisciplinary team of cancer specialists with expertise in medical oncology, surgical oncology, radiation oncology and radiology. It is crucial for highly specialized centers to collaborate via networks that aim to maintain uniformity in every aspect of treatment and rigorously gather patients' data, from the first clinical evaluation to the last follow-up visit.

The Advanced International Mini-Invasive Surgery (AIMS) academy clinical research network aims to create a rectal cancer registry. This will prospectively collect the data of patients operated on for non-metastatic rectal cancer in high volume colorectal surgical units through a well design pre-fashioned database for non-metastatic rectal cancer, in order to take all multidisciplinary aspects into consideration.

Methods/Design: The protocol describes a multicenter prospective observational cohort study, investigating demographics, frailty,

Open Peer Review

Approval Status

	1	2	3
version 1			
10 Oct 2019	view	view	view
1. Giovanni Cesana , Policlinico San Marco, Zingonia, Italy Policlinico San Marco, Zingonia, Italy			
2. Abe Fingerhut , Medical University of Graz, Graz, Austria			
3. Fabian Grass , Mayo Clinic, Rochester, USA Lausanne University Hospital CHUV,			

cancer-related features, surgical and radiological parameters, and oncological outcomes among patients with non-metastatic rectal cancer who are candidates for surgery with curative intent. Patients enrolled in the present registry will be followed up for 5 years after surgery.

Discussion: Standardization and centralization of data collection for neoplastic diseases is a virtuous process for patient care. The creation of a register will allow the control of the quality of treatments provided and permit prospective and retrospective studies to be carried out on complete and reliable high quality data. Establishing data collection in a prospective and systematic fashion is the only possibility to preserve the enormous resource that each patient represents.

Keywords

Rectal surgery, registry, network

Lausanne, Switzerland

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Giulio M. Mari (giul_mari@yahoo.it)

Author roles: **Mari GM:** Conceptualization; **Achilli P:** Writing – Original Draft Preparation; **Maggioni D:** Investigation; **Crippa J:** Writing – Review & Editing; **Costanzi ATM:** Data Curation; **Scotti MA:** Investigation; **Giardini V:** Investigation; **Garancini M:** Investigation; **Cocozza E:** Methodology; **Borroni G:** Methodology; **Benzoni I:** Project Administration; **Martinotti M:** Supervision; **Totaro L:** Project Administration; **Origi M:** Investigation; **Mazzola M:** Investigation; **Ferrari G:** Supervision; **Ziccarelli A:** Investigation; **Petri R:** Investigation; **Bagnardi V:** Data Curation, Formal Analysis, Methodology; **Pugliese G:** Software; **Forgione A:** Methodology; **Pugliese R:** Supervision;

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2019 Mari GM *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Mari GM, Achilli P, Maggioni D *et al.* **Creation of a rectal cancer registry in Italy by the Advanced International Mini-Invasive Surgery (AIMS) academy clinical research network [version 1; peer review: 3 approved]** F1000Research 2019, 8:1736 <https://doi.org/10.12688/f1000research.20702.1>

First published: 10 Oct 2019, 8:1736 <https://doi.org/10.12688/f1000research.20702.1>

Introduction

There are nearly 125,000 new cases of rectal cancer diagnosed every year in Europe, representing one of the leading causes of cancer-related morbidity and mortality world-wide¹. Five decades ago, the prognosis of rectal cancer was poor, with locoregional cancer recurrence rates of up to 40% and 5-year survival rates of <50% for locally-advanced tumors². These disappointing outcomes were improved by innovations in surgical technique, multimodality therapy and education³.

Total mesorectal excision (TME) remains the cornerstone in the treatment of non-metastatic rectal cancer. To achieve high quality TME, which is the key-factor for proper oncological resection, surgeons must respect well-known embryological planes, which were made famous as the boundaries of Heald's Holy plane⁴.

While the surgical principles for rectal cancer have changed little during the last decade, the novelties in the radiological study of the disease, as well as in the administration of neoadjuvant and adjuvant therapy, have largely modified the treatment of this neoplasm⁵. Nowadays, the management of rectal cancer is multimodal and involves a multidisciplinary team of cancer specialists with expertise in medical oncology, surgical oncology, radiation oncology and radiology. Therefore, it is becoming crucial for highly specialized centers to design pre-fashioned databases for non-metastatic rectal cancer in order to take all multidisciplinary aspects into consideration. Previous attempts to establish rectal cancer registries, such as The Norwegian Rectal Cancer Project⁶ and The Spanish Rectal Cancer Project⁷, were based on the need to first extend adequate oncological treatment, and second to increase the use of minimally invasive surgery.

The Advanced International Mini-Invasive Surgery (AIMS) academy clinical research network aims to create a rectal cancer registry that will prospectively collect data of patients operated on for non-metastatic rectal cancer in high volume colorectal surgical units, maintaining uniformity in every aspect of the treatment and rigorously gathering patients data, from the first clinical evaluation to the last follow-up visit.

Purpose

The aim of the AIMS academy clinical research network rectal cancer registry is to prospectively collect data from different minimally-invasive colorectal units in Northern Italy, with standardization of the pre-operative, intra-operative and post-operative management for patients operated on for non-metastatic rectal cancer with curative intent.

The primary outcome is to prospectively collect short and long term oncological outcomes. The second outcome is to collect information on the compliance of patients to oncological treatments, both in neoadjuvant and adjuvant settings and their quality of life.

Protocol

Study design

This protocol describes a multicenter prospective observational cohort study, investigating demographics, cancer-related features and oncological outcomes among patients who are non-metastatic rectal cancer candidates for surgery with curative intent. Patients enrolled in the present registry will be followed up for 5 years after surgery. All participating centres are public tertiary non-academic hospitals of northern Italy.

The study was approved by the Comitato Etico Scientifico Milano Area 3 (protocol number 295-052019). The study protocol has been registered as an observational study at ClinicalTrials.gov: [NCT04045236](https://clinicaltrials.gov/ct2/show/study?term=NCT04045236) (first received, 3 August 2019). All participating centres received approval from local ethics committees.

Patients and eligibility criteria

Patients receiving the diagnosis of non-metastatic rectal cancer and the indication for a curative treatment will be enrolled in the registry. The target population will consist of all patients enrolled in the participating centers from the start of the rectal cancer registry on. Patients will be identified through their medical record numbers. One investigator in each center will obtain written informed consent from each patient and keep the patients updated on data collection.

Inclusion criteria: 1) histologically proved adenocarcinoma of the rectum; 2) patient aged > 18 years old; 3) indication for surgical resection with curative intent.

Exclusion criteria: need for emergency surgery, palliative operation or metastatic disease at presentation.

Data collection

Demographic information and anamnesis with a focus on oncologic history will be recorded at the first outpatient visit, together with a complete clinical examination. Data regarding the symptoms of presentation will be collected and categorized as haemorrhagic framework, alteration of bowel habits or pain. Every patient will undergo a pre-operative staging (see Extended data: CRF1) with chest-abdominal computerized tomography scan with intravenous contrast, complete colonoscopy, pelvic magnetic resonance (MR) imaging and endorectal ultra sound (EUS) examination. Blood sample with serum level of CEA, CA 19.9 and a full nutritional panel will be collected and analysed. Charlson Comorbidities Index adjusted for age⁸ will be calculated for every patient, while those >70 years old will be assessed for frailty risk using the modified Frailty Index (mFI) described by Robinson *et al.*⁹ (see Extended data: CRF1).

All data regarding radiation doses received, total amount of chemotherapy administered and number of cycles, toxicities or adverse reaction and possible reasons for not completed treatment

schedule will be collected for all the patients with locally advance rectal cancer, who received neo adjuvant chemotherapy. Radiological restaging after neoadjuvant treatment comprises MR imaging, EUS and colonoscopy. Radiological response to neoadjuvant treatment will be measured following a uniform score system among all centers involved¹⁰. Endoscopic assessment of tumour regression will be also recorded¹¹ (see *Extended data*: CRF2).

Intraoperative analysed parameters will be included in the registry (see *Extended data*: CRF3), with special attention to technical aspects of surgical procedures, such as level of inferior mesenteric artery ligation, type of energy device used, number and type of cartridge, and size of circular stapler and all other variables detailed in the Clinical Trials registration.

Histopathological examination will be performed according to WHO 2010 guidelines¹². Macroscopic evaluation of the resected specimen will be classified according to the Quirke score¹³, while pathologic regression grade will be estimated according to a five-point scoring system¹⁴. Mismatch repair status will be reported when analysed (see *Extended data*: CRF3).

Post-operative complications will be reported according to the Clavien-Dindo scale¹⁵. Length of stay and eventual post-discharge complications will be evaluated and recorded. Application of an ERAS protocol will be considered only for at least 80% of ERAS colorectal items satisfied (see *Extended data*: CRF4)¹⁶.

Indication to adjuvant treatment will be defined within a multi-disciplinary setting. Regarding adjuvant chemotherapy, all data of interest such as number of cycles, toxicities and possible early interruption of the treatment will be collected as previously shown in the neoadjuvant setting. Oncological follow-up will be performed according to National Comprehensive Cancer Network guidelines¹⁷. One investigator in each center will carry out the follow up. Functional follow up will be done yearly according to the Low Anterior Resection Syndrome Score (see *Extended data*: CRF5)¹⁸.

Data management

Data will be collected daily using a pre-fashioned RED-CAP database by one physician for each hospital and referred to a research fellow (GMM) who will monitor the included data for all institutions. Pre-fashioned CRFs are available as *Extended data*. There will be regular contact between the study coordinators and the participating centers through scheduled meetings every three months. A data manager (GP) will regularly control the quality of the data provided.

Dissemination of the registry

All researchers will be able to access the data uploaded. Data will be hosted by the AIMS Academy. All researchers will be able to use collected data to write scientific articles or to plan surgical audits.

Study status

The registry has been enrolling patients since January 2019.

Discussion

The primary aim of this registry is to prospectively collect data from different minimally invasive colorectal units in Northern Italy with a standardization of the pre-operative, intra-operative and post-operative management for patients operated on for non-metastatic rectal cancer with curative intent.

Standardization and centralization of data collection for neoplastic diseases is a virtuous process for patient care. The creation of a register allows the control of the quality of treatments provided and permits prospective and retrospective studies to be carried out on complete and reliable high quality data.

In the last few years, the need to raise the quality of care for rectal cancer patients has been reported in numerous studies¹⁹, as well as the clear association between hospital volumes and outcomes after rectal surgery²⁰. Speaking a common language in such a complex field is no longer a benefit but rather the only way to face new challenges waiting for us in the near future.

Due to the aging population, the number of frail patients affected by rectal cancer is expected to grow²¹. As a consequence, the identification of frail patients and the need to search for tailored management able to prevent adverse complications and to improve clinical outcomes of this population will play a fundamental role in oncological surgery in the years to come²². Thus, all methods available to screen a patient for frailty, such as the Mini Cog test, the Katz Index of Independence in Activities of Daily Living (ADL), and the Timed Up and Go (TUG) test must become an integrated part of daily clinical work^{23,24}.

The accuracy achieved by pre-operative MR imaging during the last decade²⁵ has lead to important results in both preoperative staging and radiologic response evaluation after neo-adjuvant therapy²⁶. Indeed, radiologic restaging is increasingly involved in the therapeutic decision-making process²⁷. Thus, structuring a synoptic and uniform MR report must become a prerogative in management of rectal cancer patients.

As mentioned in the study protocol section, intra-operative data concerning which type of devices or staplers used during surgery will be recorded in the registry, allowing us to look for possible correlations with clinical outcomes. A well-structured prospective analysis among high volume units will help to define the real complication rate after rectal cancer surgery, which has been usually derived retrospectively and therefore potentially underestimated²⁸.

Regarding surgical expertise among the centers involved, continuous monitoring of the integrity of the resected specimens should definitely increase the overall quality of surgery.

Detailed analysis of the compliance to adjuvant chemotherapy for locally advanced rectal cancer is extremely important considering recent data reported in the literature^{29,30}. The unexpected low level of compliance reported in these previous case series has questioned the traditional administration of

adjuvant chemotherapy, searching for new strategies for locally advanced rectal tumours, such as total neoadjuvant chemotherapy³.

Conclusions

The creation of a registry for patients operated on for non-metastatic rectal cancer is a necessary requirement. Establishing data collection in a prospective and systematic fashion is the only possibility to preserve the enormous resource that each patient represents.

Data availability

Underlying data

No underlying data is associated with this article.

Extended data

Zenodo: Rectal cancer AIMS Academy clinical research network registry, <http://doi.org/10.5281/zenodo.3463627>³¹

This project contains the following extended data:

- CRF1: Patient's information and cancer staging form.
- CRF2: Neo-adjuvant chemoradiotherapy and cancer restaging form.
- CRF3: Surgery, surgical outcomes and pathological examination form.
- CRF4: Adjuvant chemotherapy form.
- CRF5: Oncological follow-up form.

Data are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

Acknowledgements

AIMS Academy: www.aimsacademy.org

References

1. European cancer information system: **Estimates of cancer incidence and mortality in 2018, for all countries**. European commission. [Reference Source](#)
2. Slaney G: **Results of treatment of carcinoma of the colon and rectum**. *Mod Trends Surg*. 1971; 3: 69–89. [PubMed Abstract](#)
3. Zaborowski A, Stakelum A, Winter DC: **Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancer**. *Br J Surg*. 2019; 106(8): 979–987. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Heald RJ, Moran BJ, Ryall RD, *et al.*: **Rectal cancer: The Basingstoke experience of total mesorectal excision, 1978–1997**. *Arch Surg*. 1998; 133(8): 894–9. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Al-Sukhni E, Milot L, Fruitman M, *et al.*: **Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis**. *Ann Surg Oncol*. 2012; 19(7): 2212–23. [PubMed Abstract](#) | [Publisher Full Text](#)
6. Wibe A, Møller B, Norstein J, *et al.*: **A national strategic change in treatment policy for rectal cancer—implementation of total mesorectal excision as routine treatment in Norway. A national audit**. *Dis Colon Rectum*. 2002; 45(7): 857–66. [PubMed Abstract](#) | [Publisher Full Text](#)
7. Ortiz H, Ciga MA, Armendariz P, *et al.*: **Multicentre propensity score-matched analysis of conventional versus extended abdominoperineal excision for low rectal cancer**. *Br J Surg*. 2014; 101(7): 874–882. [PubMed Abstract](#) | [Publisher Full Text](#)
8. Charlson M, Pompei P, Ales KL, *et al.*: **A new method of classifying prognostic comorbidity in longitudinal studies: development and validation**. *J Chronic Dis*. 1987; 40(5): 373–383. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Robinson TN, Wu DS, Pointer L, *et al.*: **Simple frailty score predicts postoperative complications across surgical specialties**. *Am J Surg*. 2013; 206(4): 544–550. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Beets-Tan RGH, Lambregts DMJ, Maas M, *et al.*: **Correction to: Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting**. *Eur Radiol*. 2018; 28(6): 2711. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Sohn DK, Han KS, Kim BC, *et al.*: **Endoscopic assessment of tumor regression after preoperative chemoradiotherapy as a prognostic marker in locally advanced rectal cancer**. *Surg Oncol*. 2017; 26(4): 453–459. [PubMed Abstract](#) | [Publisher Full Text](#)
12. Ft B, F C, Rh H, *et al.*: **WHO classification of tumours of the digestive system**. *J Clin Ultrasound*. 2014.
13. Quirke P, Dixon MF, Durdey P, *et al.*: **Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision**. *Lancet*. 1986; 2(8514): 996–9. [PubMed Abstract](#) | [Publisher Full Text](#)
14. Ryan R, Gibbons D, Hyland JMP, *et al.*: **Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer**. *Histopathology*. 2005; 47(2): 141–146. [PubMed Abstract](#) | [Publisher Full Text](#)
15. Dindo D, Demartines N, Clavien PA: **Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey**. *Ann Surg*. 2004; 240(2): 205–213. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Gustafsson UO, Scott MJ, Hubner M, *et al.*: **Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations: 2018**. *World J Surg*. 2019; 43(3): 659–695. [Publisher Full Text](#)
17. NCCN guidelines version 4.2018: **Colon Cancer**. © National Comprehensive Cancer Network, Inc. All Rights Reserved. 2014. [Reference Source](#)
18. Emmertsen KJ, Laurberg S: **Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer**. *Ann Surg*. 2012; 255(5): 922–928. [PubMed Abstract](#) | [Publisher Full Text](#)
19. Merchea A, Ali SM, Kelley SR, *et al.*: **Long-Term Oncologic Outcomes of Minimally Invasive Proctectomy for Rectal Adenocarcinoma**. *J Gastrointest Surg*. 2018; 22(8): 1412–1417. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Hagemans JAW, Alberda WJ, Verstegen M, *et al.*: **Hospital volume and outcome in rectal cancer patients; results of a population-based study in the Netherlands**. *Eur J Surg Oncol*. 2019; 45(4): 613–619. [PubMed Abstract](#) | [Publisher Full Text](#)
21. Clegg A, Young J, Iliffe S, *et al.*: **Frailty in elderly people**. *Lancet*. 2013; 381(9868): 752–762. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Fagard K, Leonard S, Deschodt M, *et al.*: **The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: A systematic review**. *J Geriatr Oncol*. 2016; 7(6): 479–491. [PubMed Abstract](#) | [Publisher Full Text](#)
23. Ghignone F, Van Leeuwen BL, Montroni I, *et al.*: **The assessment and management of older cancer patients: A SIOP surgical task force survey on surgeons' attitudes**. *Eur J Surg Oncol*. 2016; 42(2): 297–302. [PubMed Abstract](#) | [Publisher Full Text](#)
24. Montroni I, Rostoft S, Spinelli A, *et al.*: **GOSAFE - Geriatric Oncology Surgical Assessment and Functional Recovery after Surgery: early analysis on 977 patients**. *J Geriatr Oncol*. 2019; pii: S1879-4068(19)30168-7. [PubMed Abstract](#) | [Publisher Full Text](#)
25. Kennedy ED, Simunovic M, Jhaveri K, *et al.*: **Safety and Feasibility of Using**

- Magnetic Resonance Imaging Criteria to Identify Patients with "good Prognosis" Rectal Cancer Eligible for Primary Surgery: The Phase 2 Nonrandomized QuickSilver Clinical Trial.** *JAMA Oncol.* 2019; 5(7): 961–966.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Siddiqui MRS, Bhoday J, Battersby NJ, *et al.*: **Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales.** *World J Gastroenterol.* 2016; 22(37): 8414–8434.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Bhoday J, Balyasnikova S, Wale A, *et al.*: **How Should Imaging Direct/Orient Management of Rectal Cancer?.** *Clin Colon Rectal Surg.* 2017; 30(5): 297–312.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 28. Lin Z, Jiang ZL, Chen DY, *et al.*: **Short- and long-term outcomes of laparoscopic versus open surgery for rectal cancer.** *Medicine (Baltimore).* 2018; 97(50): e13704.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. Bosset JF, Calais G, Mineur L, *et al.*: **Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: Long-term results of the EORTC 22921 randomised study.** *Lancet Oncol.* 2014; 15(2): 184–9010.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Mari GM, Maggioni D, Crippa J, *et al.*: **Compliance to Adjuvant Chemotherapy of Patients Who Underwent Surgery for Rectal Cancer: Report from a Multi-institutional Research Network.** *World J Surg.* 2019; 43(10): 2544–2551.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Mari G, Achill P: **Rectal cancer AIMS Academy clinical research network registry.** *Zenodo.* 2019.
<http://www.doi.org/10.5281/zenodo.3463627>

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 14 November 2019

<https://doi.org/10.5256/f1000research.22769.r55725>

© 2019 Grass F. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fabian Grass

¹ Department of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA

² Lausanne University Hospital CHUV, Lausanne, Switzerland

The Northern Italian research group presents a study protocol detailing specifics of a rectal cancer registry, which consists of a multicentric collaboration aiming to gather reliable, prospectively collected data for rectal cancer research. The authors need to be congratulated for their initiative. Multi-institutional collaborations are needed in the rapidly evolving field of multi-modal treatment of locally advanced rectal cancer. The authors emphasise new challenges of an ageing, frail population. Radiotherapy- or surgery-sparing strategies may represent interesting alternatives to conventional treatment schemes.

Overall the protocol is clear and concise. I would like to suggest expanding on the following points:

- Multi-institutional collaborations are challenging, since dealing with a heterogeneous patient- and provider population, surgical and perioperative care. How do the authors account for that?
- Standardization: Do all centers use similar treatment protocols? How standardized is the surgical approach? Do all centers perform robotic proctectomy? How experienced are participating surgeons? Are all participating centers teaching facilities?
- I think the authors may expand on complication assessment. Who is assessing complications, are these institution-specific abstractors or do centers dispose of surveillance tools, i.e. for surgical site infections?
- How do the authors ascertain data quality? National data registries ideally need (independent) audit and validation. Who is auditing data accuracy?

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Colorectal surgery, minimally-invasive surgery

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 05 November 2019

<https://doi.org/10.5256/f1000research.22769.r55011>

© 2019 Fingerhut A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abe Fingerhut

Section for Surgical Research, Department of Surgery, Medical University of Graz, Graz, Austria

This registry is unique and essential to research in Italy.

The Advanced International Mini-Invasive Surgery (AIMS) academy clinical research network has a major role in this multicenter prospective observational cohort study, I agree that standardization and centralization of data collection for neoplastic diseases is essential for patient care. The creation of a register will allow the control of the quality of treatments provided and permit prospective and retrospective studies to be carried out on complete and reliable high quality data.

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Surgery and clinical research

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 17 October 2019

<https://doi.org/10.5256/f1000research.22769.r55012>

© 2019 Cesana G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Giovanni Cesana

¹ Department of Surgery, S.I.C.OB. (Italian Society of Bariatric Surgery) Referral Center for Bariatric Surgery, San Donato Group, Policlinico San Marco, Zingonia, Italy

² Policlinico San Marco, Zingonia, Italy

This paper describes the creation of a national registry for non metastatic rectal cancer. The main issue is a high quality standardization of rectal cancer multimodal treatment, staging and follow up.

I think that the core of the project is well explained and clarified. Additional materials are clear and quite user friendly.

The methods are well described and expanded enough.

The need for well designed databases on rectal cancer is clearly expressed by the literature.

I believe that this registry represents a high quality attempt in the direction of a centralized and appropriate treatment for rectal cancer.

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Colorectal surgery

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research